Clinical studies recruiting near Rock Hill

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C
Phase 3 · Rock Hill Radiation Therapy Center · NRG Oncology · NCT05624996 Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient
Phase 2 · Rock Hill Radiation Therapy Center · NRG Oncology · NCT06532279 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · NRG Oncology · NCT05174169 Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastati
Phase 3 · Alliance for Clinical Trials in Oncology · NCT06931340 ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · Alliance for Clinical Trials in Oncology · NCT06876714 A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
Phase N/A · Clinical Research of Rock Hill - Site Number: 840115 · Sanofi · NCT07556159 Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and S
Phase 3 · Levine Cancer Institute-Rock Hill · Canadian Cancer Trials Group · NCT06592924 E-Mindfulness Approaches for Living After Breast Cancer
Phase 3 · Levine Cancer Institute-Rock Hill · NRG Oncology · NCT06748222 A Study to Evaluate Solrikitug in Participants With COPD (ZION)
Phase 2 · Clinical Research of Rock Hill · Uniquity One (UNI) · NCT06496620 Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Phase N/A · Alliance for Clinical Trials in Oncology · NCT04242095 De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Eq
Phase 3 · Rock Hill Radiation Therapy Center · NRG Oncology · NCT04852887 mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · Alliance for Clinical Trials in Oncology · NCT05677490 Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NA · NRG Oncology · NCT05080673 Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Phase N/A · ECOG-ACRIN Cancer Research Group · NCT04239573 Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Remo
Phase 2/Phase 3 · Levine Cancer Institute-Rock Hill · National Cancer Institute (NCI) · NCT05987241 Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Phase 2 · Levine Cancer Institute-Rock Hill · SWOG Cancer Research Network · NCT04205968 A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD
Phase 3 · Clinical Research of Rock Hill · Hoffmann-La Roche · NCT05878769 S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac
Phase 3 · SWOG Cancer Research Network · NCT03418961 Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Phase N/A · ECOG-ACRIN Cancer Research Group · NCT06002828 S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic
NA · SWOG Cancer Research Network · NCT03723928 The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Phase 3 · Clinical Research of Rock Hill · Boehringer Ingelheim · NCT06872892 Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabo
Phase 2 · National Cancer Institute (NCI) · NCT03866382 Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung
Phase 3 · National Cancer Institute (NCI) · NCT04267848 Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants
Phase 2 · Clinical Research of Rock Hill · Altesa Biosciences, Inc. · NCT07610395 Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Phase 3 · ECOG-ACRIN Cancer Research Group · NCT03937635 Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Phase 2/Phase 3 · SWOG Cancer Research Network · NCT03851445 High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Che
Phase 3 · Alliance for Clinical Trials in Oncology · NCT06992427 Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Phase 3 · National Cancer Institute (NCI) · NCT04181060 Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After
Phase 3 · Levine Cancer Institute-Rock Hill · Alliance for Clinical Trials in Oncology · NCT05812807 Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ C
Phase 3 · Children's Oncology Group · NCT03067181

Look up another city

Look up another condition